Leukemia
1,666
102
144
1,060
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
381 trials with published results (23%)
Research Maturity
1060 completed trials (64% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.1%
218 terminated out of 1666 trials
82.9%
-3.6% vs benchmark
9%
154 trials in Phase 3/4
36%
381 of 1060 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1060 completed trials
Clinical Trials (1666)
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Rutgers University Study of the Genetics of Blood Cancers
AZD6738 for Patients With Progressive MDS or CMML
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Case-Control Study of Pesticides and Childhood Leukemia
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes